Strides to sell manufacturing facility in Singapore for Rs 125 crore

"Proceeds from the transaction will be utilized for debt reduction," Strides stated.

Published On 2023-10-29 10:30 GMT   |   Update On 2023-10-29 10:30 GMT
Advertisement

Bangalore: Strides Pharma Science Limited has announced that its step‐ down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has entered into binding agreement with Rxilient Biohub Pte. Ltd. for the sale of its manufacturing facility including licenses, equipment, vendor contracts, etc. for a total cash consideration of $15m.

As part of the transaction, Rxilient Biohub will also take over the long term lease obligation of the manufacturing site from Strides. The manufacturing site was mothballed last year as part of the manufacturing network optimization and cost reduction programs announced as part of FY23 resetstrategy.

"Efforts were focused in integrating the US and the products that were supplied for US government procurement have been transferred to the Chestnut Ridge, US manufacturing site. This transaction is the culmination of the manufacturing network optimization efforts as we continue to focus on driving profitability and operational efficiency," Strides stated in a release.

"This sale will help further reduce annual costs by ~$9m (~ ₹750m), of which ~$2m (~₹180m) reduction in operating expenses ( EBITDA accretive) and ~$7m (~₹570m) in Depreciation and operating lease expenses, thereby being immediately accretive to EPS ( annualized ~ ₹ 7/share)," the Company stated.

The transaction is expected to close in Q3FY24 on receipt of necessary approvals and completion of customary & other closing conditions.

"Proceeds from the transaction will be utilized for debt reduction," it added.

Rxilient Biohub, incorporated in Singapore, is mainly engaged in manufacture of pharmaceutical products and preparations for human use and manufacture of vaccines for human use. Rxilient Biohub plans to start CDMO business in Singapore.

Read also: Strides Pharma bags USFDA nod for Efavirenz, Emtricitabine, Tenofovir Disproxil Fumurate tablets for HIV

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News